PERSONALIZED MEDICINE INITIATIVE



Table Of Content

- 01 Problem Statement
- 02 Stakeholders
- 03 Methodology
- 04 Recommended Analysis
- 05 Conclusion



Problem Statement

Pfizer aims to improve treatment effectiveness by tailoring drugs to individual patients through personalized medicine. This project seeks to analyze clinical trial and genomics data to identify key patient demographics and genetic factors that influence drug efficacy and side effect patterns. By uncovering these insights, Pfizer can develop more effective, targeted treatments, enhance clinical trial designs, and reduce adverse side effects for diverse patient groups. This data-driven approach will help Pfizer advance the future of precision medicine.

Stakeholders

- Internal Stakeholders: Pfizer's Research and Development (R&D) team, Data Science Team, and Clinical Researchers.
- External Stakeholders: Medical professionals, regulatory bodies, and patients.







Positive Mutations
471



Success Rate

34.70%



Avg Survival Rate
(In Months)
14.96





Average Efficacy
Score

5.4




Average Progression
Free Survival
11.59



Avg Survival Rate
(In Months)
14.96

Recommended Analysis


Q1. Analyze the number of patients in each age group?



Recommended Analysis

Q2. Analyze the number of side effects reported by drug?





Recommended Analysis

Q3. Analyze Trend Over Time Survival Time?





Mutation_Status

Side_Effects

Total Positive Mutations

Mutation_Status 471



Success Rate %

34.7%

Success Rate



Average Survival

Survival Rate(in Months) 14.96



Average Efficacy Score

Efficacy_Score

5.4




Average PFS Progression_Free_Survival


11.59



Survival Rate Over Time



Side Effect by Drug



Average Efficacy Score by Drugs











Gender

Side_Effects

Average PFS

Total Positive Mutations

Mutation_Status 471



Success Rate

Success Rate % 34.7%



Average Survival

Survival Rate(in Months)

14.96



Average Efficacy Score

Progression_Free_Survival 11.59




Avg Ethnicity by Drug and Age Group













No. of Patients by Ethnicity



Drug Distribution by Trial Phase





Ethnicity -

Side_Effects

Total Positive Mutations

Mutation_Status
471

Success Rate

34.7%

6

Average Survival

Survival Rate(in Months)

14.96

Average Efficacy Score

Efficacy_Score

5.4

Average PFS

Progression_Free_Survival


11.59









Biomarker Level by Treatment



No. of Patients by Gender



Avg Survival Rate by Gender and Drugs













Drug_Name

Genomic_Profile

Total Positive Mutations

Success Rate

Success Rate %

34.7%

Average Survival

Average Efficacy Score

Average PFS

Mutation_Status

471




Survival Rate(in Months) 14.96


Efficacy_Score 5.4

11.59




Avg Survival Rate by Ethnicity and Mutations






Avg Dose by Age Group



Avg Efficacy Score by Age Group and Gender











THANK YOU

